PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financia... ( ANNAPOLIS Md. April 3 2012 /- PharmAt...)

PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services

Date:4/3/2012

ANNAPOLIS, Md., April 3, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) today announced that it has secured $7.5 million in senior secured credit facilities from GE Capital, Healthcare Financial Services consisting of a $2.5 million term loan and a revolving line of credit of up to $5 million.

Linda L. Chang, Senior Vice President and Chief Financial Officer, commented, "We are very pleased to partner with GE Capital – a recognized leader in healthcare financing. This financing further strengthens our balance sheet and provides us with increased flexibility to manage our working capital requirements."

"Our expected 2012 monthly cash burn is less than $500,000 per month based on currently projected activities on our contracts," Ms. Chang continued. "Given that PharmAthene had $19.2 million in cash and cash equivalents, short term investments, and net receivables as of December 31, 2011, this financing provides an additional liquidity cushion until the time in 2013 when we anticipate receiving final resolution of the litigation with SIGA Technologies."

For a summary of the terms of the credit facility, see the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date hereof.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

SparVax™ – a second generation recombinant protective antigen (rPA) anthrax vaccine
Valortim® – a fully human monoclonal antibody for the prevention and treatment of anthrax infection
Recombinant BChE – a novel bioscavenger for
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related biology technology :

1. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
2. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
3. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
4. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
5. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
6. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
7. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
8. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
9. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
10. PharmAthene Completes $6.5 Million Registered Direct Offering
11. PharmAthene Reports First Quarter 2011 Financial and Operating Results

Post Your Comments:

(Date:5/17/2013)... 17, 2013 Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...

(Date:5/17/2013)... May 17, 2013 Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy. The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board. In this study, INS001 ...

(Date:5/17/2013)... (PRWEB) May 17, 2013 RURO ... ezColony version 4.1, a versatile refinement to the ... software solution, improves its advanced methodical management for ... with ezColony 4.1. The network-based platform provides user ... effective research. While continuing to emphasize streamlined tasks, ...

(Date:5/17/2013)... Darrington, WA (PRWEB) May 17, 2013 Tooth ... 5th graders showing active signs of the disease. The World ... children and nearly 100% of adults have cavities. What are ... Research is showing a strong connection between the oral ... why is this disease so rampant, yet it is also ...

Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2 Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2 RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2 Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2 Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3

[0] Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis [0] Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy [0] RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software [0] Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay

... 31 Schering-Plough,Corporation (NYSE: SGP ) today ... has accepted the Peg-IFN (peginterferon alfa-2b),supplemental Biologics License ... status for the adjuvant treatment of patients with,Stage ... agency,in the fall of 2007., The Priority ...

... Jan. 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... webcast live during the 10th Annual BIO CEO ... 1:15 p.m. Eastern Time., The presentation will ... To access the live presentation via the Web, ...

... and Backlog Increase to Record Highs, BEDFORD, Mass., ... diversified medical technologies company specializing in,diagnostics, imaging systems and ... today announced its results for the,quarter ended December 29, ... -- Record revenues of $371.4 million. -- Merger ...

FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference Hologic Announces First Quarter Fiscal 2008 Operating Results

(Date:5/16/2013)... adults living closer to a fast food restaurant had ... lived further away from fast food, according to researchers ... and this association was particularly strong among those with ... online in the American Journal of Public Health ... a fast food restaurant, and among lower-income African-Americans, the ...

(Date:5/16/2013)... CAMBRIDGE, MA -- Injectable nanoparticles developed at MIT ... Type 1 diabetes to constantly monitor their blood-sugar ... nanoparticles were designed to sense glucose levels in ... amount of insulin, thereby replacing the function of ... with Type 1 diabetes. Ultimately, this type of ...

(Date:5/16/2013)... do so many sports players and athletes choose to ... study to be published in Psychological Science , ... that it may have to do with their testosterone ... Daniel Farrelly of the University of Sunderland and colleagues, ... in a competitive task had higher testosterone levels than ...

Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2 Body mass index of low income African-Americans linked to proximity of fast food restaurants 3 Nanotechnology could help fight diabetes 2 Nanotechnology could help fight diabetes 3 High-testosterone competitors more likely to choose red 2

[0] Body mass index of low income African-Americans linked to proximity of fast food restaurants [0] Nanotechnology could help fight diabetes [0] High-testosterone competitors more likely to choose red

... what the doctor orders for individuals suffering from dry eye ... tear film composition. According to a study published in ... 30 degrees Celsius on the eye and eyelid could be ... The study, (Meibomian Lipid Films and the Impact of ...

... How well our brain functions is largely based on ... led study. The study published in the international publication ... of a genetic effect on how ,cost-efficient, our brain network ... up. Lead author Dr Alex Fornito from the Melbourne ...

... the food web each spring in places like the Arctic ... the first published findings about this ability. The same ... antifreeze against temperatures well below minus 10 C is also ... that are hospitable to itself and other microorganisms. Altering ...

Cached Biology News:Drop in temperature may explain the increase in dry eye suffering 2 Better brain wiring linked to family genes 2 Algal antifreeze makes inroads into ice 2

Drop in temperature may explain the increase in dry eye suffering Better brain wiring linked to family genes Algal antifreeze makes inroads into ice

Mouse HAI-1 Ectodomain MAb (Clone 199732)...

pETDuet-1 is designed for the coexpression of two target genes....

Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...

Mouse Laminin-1 MAb (Clone AL-3)...

Biology Products:

Rat Anti-Mouse HAI-1 Ectodomain Monoclonal Antibody, Unconjugated, Clone 199732 from R&D Systems pETDuet-1 from Novagen Goat Anti-Human IL-29 / IFN-lambda 1 Polyclonal Antibody, Biotin Conjugated from R&D Systems Anti-Mouse Laminin-1 Monoclonal Antibody, Unconjugated, Clone AL-3 from R&D Systems